{
    "nctId": "NCT00373256",
    "briefTitle": "A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 488,
    "primaryOutcomeMeasure": "Progression-Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of advanced breast cancer.\n* Measurable disease as per RECIST (Response Evaluation Criterion) in Solid Tumors or bone-only disease.\n* ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.\n\nExclusion Criteria:\n\n* No prior treatment with cytotoxics in the advanced disease setting.\n* HER2/neu positive disease unless trastuzumab was previously received or is contraindicated.\n* Treatment with a taxane in the adjuvant setting unless disease free interval \\>12 months after end of treatment.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}